Nature Medicine: April 4, 2013
With the precipitously falling price of genome sequencing, generating reams of data is easy these days—analyzing all those As, Ts, Cs and Gs is the hard part. Yet, it’s not just physicians and scientists who are faced with this analytical bottleneck posed by high-throughput sequencing (HTS). Regulators are now receiving huge batches of sequence data that support new drug applications—and they are struggling to figure out what to do with them.
High-throughput sequencing technology produces millions of sequences all at once in an automated and parallel fashion. Because of its high-throughput nature, it outperforms the time efficiency of the older Sanger sequencing by a factor of 1,000 and allows researchers to obtain an entire genome from an individual in a matter of days. Read more